{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:31:17Z","timestamp":1781796677236,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blinatumomab, a bispecific T-cell engager (BiTE), has significantly improved the efficacy of B-ALL treatment. However, its association with immune effector cell-associated neurotoxicity syndrome (ICANS) has garnered increasing attention. This study analyzes two cases of ICANS to explore the challenges in recognizing clinical symptoms and standardizing management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      Case 1 involved a 69-year-old male with B-ALL, harboring\n                      <jats:italic>TP53<\/jats:italic>\n                      and\n                      <jats:italic>DNMT3A<\/jats:italic>\n                      mutations, who developed grade 2 ICANS following blinatumomab treatment. Therapy was continued without interruption, and symptoms resolved with levetiracetam intervention. Case 2 was a 29-year-old male with B-ALL and\n                      <jats:italic>ETV6::RUNX1<\/jats:italic>\n                      fusion gene, who developed grade 4 ICANS (seizures, impaired consciousness, epileptic episodes) on day 4 of blinatumomab therapy. The patient required intensive care and comprehensive intervention, leading to symptom resolution but discontinuation of treatment. Neither case exhibited central nervous system infiltration, and cranial CT scans showed no abnormalities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion<\/jats:title>\n                    <jats:p>ICANS may be associated with cytokine release, blood-brain barrier disruption, and genetic background, presenting with heterogeneous symptoms. Elderly patients or those with specific genetic mutations may face increased risks, necessitating individualized dose adjustments (e.g., stepwise dosing) and close monitoring of neurological functions and cytokines (e.g., IL-6). Early recognition of subtle symptoms (e.g., tremors) combined with corticosteroids and antiepileptic drugs can improve outcomes. The use of blinatumomab requires careful balancing of efficacy and neurotoxicity, particularly in high-risk patients. This case report provides valuable insights for the clinical recognition and management of ICANS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1743310","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:28:15Z","timestamp":1771824495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Safety analysis of blinatumomab consolidation therapy in two cases of acute B-cell lymphoblastic leukemia in complete remission complicated with immune effector cell-associated neurotoxicity syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Yixuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"Loffler","year":"2003","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80425\u20132","article-title":"The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules","volume":"6","author":"Prigozy","year":"1997","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000507","article-title":"Neurotoxicity biology and management","volume":"27","author":"Danish","year":"2021","journal-title":"Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20240528\u201300194","article-title":"Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia","volume":"45","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2021.06.051","article-title":"Interpretation of ASTCT consensus responses by chimeric antigen receptor T cell therapy CRS\/ICANS--review","volume":"29","author":"Fu","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05\u2013552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/cancers13153912","article-title":"Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: A systematic review and meta-analysis","volume":"13","author":"Lei","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2230888","article-title":"Blinatumomab as salvage therapy in patients with relapsed\/refractory B-ALL who have failed\/progressed after anti-CD19-CAR T therapy","volume":"55","author":"Qi","year":"2023","journal-title":"Ann Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","article-title":"Level of myoglobin in serum of patients with epilepsy after generalized tonic-clonic seizure","volume":"47","author":"Pokrzywnicki","year":"1994","journal-title":"Wiad Lek"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422006","article-title":"Hypernatremia","volume":"342","author":"Adrogue","year":"2000","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1743310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:28:17Z","timestamp":1771824497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1743310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1743310"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1743310","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1743310"}}